Allogene Therapeutics Conference Call - ALLOGENE THERAPEUTICS INC

Explicit Guidance:

• No quantitative financial guidance (revenue, earnings, margins, or cash flow) provided.
• No specific timing for Phase 2 initiation or registration data release announced; management indicated decisions on cohort expansion and Phase 2 design will be made "in relative short order" following further data collection on safety and efficacy.

Business-Segment Outlook:

• Resolution Trial (ALLO329): Proceeding with dose escalation and expanding cohorts; shifting focus from a broad basket design (scleroderma, lupus, myositis) to specific focus on scleroderma.
• Target Patient Cohort: Aiming to treat "initial treatment-refractory scleroderma" patients; early efficacy observed in patients with median disease duration of 24–28 months.
• Efficacy Expectations: Anticipate continued deepening of clinical activity over time; early data shows improved skin scores (MRSS) within 14 days, with some patients reducing scores by 14+ points by month 3.
• Durability: Management expects CAR-T cells to eventually "peter out" (non-persistent), which is viewed as a benefit to allow return to normal immune function, rather than requiring indefinite persistence for efficacy.
• Treatment Regimen: Exploring viability of administering therapy without lymphodepletion (chemo-free) to reduce toxicity and enable outpatient delivery.

Market and Competitive Outlook:

• Differentiation: Positioning ALLO329 as an "off-the-shelf" allogeneic product distinct from autologous CAR-T, designed to reduce treatment burden, complexity, and risk of opportunistic infections associated with chemotherapy.
• Biomarker Shift: Challenging the industry standard that complete B-cell aplasia is required for efficacy; suggesting that CD19/CD70 dual targeting and T-cell modulation may drive efficacy without deep peripheral B-cell depletion.
• Competitive Landscape: Acknowledges recent industry pauses due to high-grade toxicities in other allogeneic CAR-T programs; positions ALLO329's safety profile (Grade 1-2 CRS only, no ICANS/IGVHD observed to date) as a competitive advantage.
• Clinical Practice: Envisioning potential for outpatient administration due to off-the-shelf availability and lack of need for hospitalization associated with lymphodepletion.

Macro / Industry Outlook:

• Safety Standards: Management notes a shift in the wider CAR-T space toward prioritizing safety to avoid study pauses, influencing Allogene's decision to de-escalate lymphodepletion requirements.
• Immunosuppression Risks: Highlights the broader industry risk of prolonged immunosuppression and opportunistic infections associated with heavy conditioning chemotherapy; aims to mitigate this via reduced toxicity regimens.
• Unmet Need: Emphasizes the lack of approved treatments for skin involvement in scleroderma and the high burden of long-term immunosuppressive therapies in the autoimmune market.

Strategic Initiatives:

• Trial Design Evolution: Transitioning from a first-in-human dose escalation (currently 18 patients enrolled) to an expanded cohort strategy to gather robust data for Phase 2 design.
• Catalysts: Upcoming catalysts include completion of dose escalation, data from expanded cohorts, and finalization of the Phase 2 regimen.
• Timeline: Explicitly stated plan to "build on these results" in 2027 as part of the continued dose expansion and Phase 2 development strategy.
• Commercialization Prep: Early discussions regarding the feasibility of outpatient treatment delivery and potential expansion to other autoimmune indications.

Risks and Headwinds to Outlook:

• Durability Uncertainty: Unknown duration of response; preliminary data shows one patient with MRSS worsening after initial improvement (patient 6) and another with response pausing before deepening.
• Mechanism of Resistance: Current inability to definitively explain why some patients progress or fail to maintain response; further investigation into mechanisms of resistance is ongoing.
• Trial Scope: Lung involvement data is currently considered "too early" to report; stability is observed but not yet a proven efficacy signal.
• Regulatory/Market: Reliance on continued positive safety signals to avoid study pauses common in the broader CAR-T sector; potential for high-grade toxicities if lymphodepletion is adjusted incorrectly.

Management Tone on the Future:

• Confidence Level: "Very pleased," "encouraging," and "cautiously optimistic." Management expresses strong confidence in the safety profile and the speed of early clinical response.
• Strategic Shift: Expresses a clear intent to move away from "repurposing oncology CAR-T" toward a differentiated autoimmune protocol that prioritizes lower toxicity over maximal B-cell depletion.
• Hedges: Repeatedly emphasizes that data is "preliminary," "early," and "preclinical/early human" results may not translate to long-term durability.

Miscellaneous:

• Safety Data: 18 patients treated; 0 dose-limiting toxicities (DLT), 0 ICANS, 0 GvHD, 0 Grade 3+ CRS. Four cases of Grade 1-2 CRS.
• Immunosuppression: 9 of 10 efficacy patients remained off background immunosuppressive therapy post-treatment.
• Clinical Metrics: 8 of 10 scleroderma patients achieved a 5-point Minimal Clinically Important Difference (MCID) on MRSS; some achieved >10-point reduction.